Performance of Three Anti-SARS-CoV-2 Anti-S and One Anti-N Immunoassays for the Monitoring of Immune Status and Vaccine Response

Y. Victoria Zhang,Attila Kumanovics,Joesph Wiencek,Stacy E. F. Melanson,Tanzy Love,Alan H. B. Wu,Zhen Zhao,Qing H. Meng,David D. Koch,Fred S. Apple,Caitlin R. Ondracek,Robert H. Christenson
DOI: https://doi.org/10.3390/v16020292
2024-02-16
Viruses
Abstract:This study aimed to evaluate and compare the performance of three anti-S and one anti-N assays that were available to the project in detecting antibody levels after three commonly used SARS-CoV-2 vaccines (Pfizer, Moderna, and Johnson & Johnson). It also aimed to assess the association of age, sex, race, ethnicity, vaccine timing, and vaccine side effects on antibody levels in a cohort of 827 individuals. In September 2021, 698 vaccinated individuals donated blood samples as part of the Association for Diagnostics & Laboratory Medicine (ADLM) COVID-19 Immunity Study. These individuals also participated in a comprehensive survey covering demographic information, vaccination status, and associated side effects. Additionally, 305 age- and gender-matched samples were obtained from the ADLM 2015 sample bank as pre-COVID-19-negative samples. All these samples underwent antibody level analysis using three anti-S assays, namely Beckman Access SARS-CoV-2 IgG (Beckman assay), Ortho Clinical Diagnostics VITROS Anti-SARS-CoV-2 IgG (Ortho assay), Siemens ADVIA Centaur SARS-CoV-2 IgG (Siemens assay), and one anti-N antibody assay: Bio-Rad Platelia SARS-CoV-2 Total Ab assay (BioRad assay). A total of 827 samples (580 COVID-19 samples and 247 pre-COVID-19 samples) received results for all four assays and underwent further analysis. Beckman, Ortho, and Siemens anti-S assays showed an overall sensitivity of 99.5%, 97.6%, and 96.9%, and specificity of 90%, 100%, and 99.6%, respectively. All three assays indicated 100% sensitivity for individuals who received the Moderna vaccine and boosters, and over 99% sensitivity for the Pfizer vaccine. Sensitivities varied from 70.4% (Siemens), 81.5% (Ortho), and 96.3% (Beckman) for individuals who received the Johnson & Johnson vaccine. BioRad anti-N assays demonstrated 46.2% sensitivity and 99.25% specificity based on results from individuals with self-reported infection. The highest median anti-S antibody levels were measured in individuals who received the Moderna vaccine, followed by Pfizer and then Johnson & Johnson vaccines. Higher anti-S antibody levels were significantly associated with younger age and closer proximity to the last vaccine dose but were not associated with gender, race, or ethnicity. Participants with higher anti-S levels experienced significantly more side effects as well as more severe side effects (e.g., muscle pain, chills, fever, and moderate limitations) (p < 0.05). Anti-N antibody levels only indicated a significant correlation with headache. This study indicated performance variations among different anti-S assays, both among themselves and when analyzing individuals with different SARS-CoV-2 vaccines. Caution should be exercised when conducting large-scale studies to ensure that the same platform and/or assays are used for the most effective interpretation of the data.
virology
What problem does this paper attempt to address?
This paper aims to evaluate and compare the performance of three anti - S protein (anti - S) and one anti - N protein (anti - N) immunoassays in detecting antibody levels after vaccination with three common SARS - CoV - 2 vaccines (Pfizer, Moderna, and Johnson & Johnson). Meanwhile, the study also explored the effects of factors such as age, gender, race, ethnicity, vaccination time, and vaccine side effects on antibody levels. The study subjects were 827 individuals, including 698 vaccinated individuals and 305 age - and gender - matched uninfected individuals from a 2015 sample bank. ### Main Objectives: 1. **Evaluate antibody levels after different vaccines**: Evaluate the antibody levels of individuals after vaccination with Pfizer, Moderna, and Johnson & Johnson vaccines through three anti - S protein and one anti - N protein immunoassays. 2. **Compare the performance of different assays**: Evaluate the sensitivity and specificity of these assays and compare their performance in different vaccinated populations. 3. **Analyze the effects of demographic factors and vaccine side effects on antibody levels**: Explore the effects of factors such as age, gender, race, ethnicity, vaccination time, and vaccine side effects on antibody levels. ### Research Methods: - **Sample collection**: Collect blood samples from 698 vaccinated individuals and obtain blood samples from 305 uninfected individuals in the 2015 sample bank. - **Assays**: Use three anti - S protein assays (Beckman Access SARS - CoV - 2 IgG, Ortho Clinical Diagnostics VITROS Anti - SARS - CoV - 2 IgG, Siemens ADVIA Centaur SARS - CoV - 2 IgG) and one anti - N protein assay (Bio - Rad Platelia SARS - CoV - 2 Total Ab assay) for antibody level analysis. - **Data analysis**: Evaluate the performance of each assay through receiver operating characteristic curve (ROC) analysis and calculation of positive predictive value (PPV) and negative predictive value (NPV). At the same time, use a linear model to analyze the relationship between antibody levels and demographic and clinical variables. ### Main Findings: - **Assay performance**: - **Anti - S protein assays**: The overall sensitivities of Beckman, Ortho, and Siemens were 99.5%, 97.6%, and 96.9% respectively, and the specificities were 90%, 100%, and 99.6% respectively. - **Anti - N protein assay**: The sensitivity of Bio - Rad was 46.2% and the specificity was 99.2%. - **Effect of vaccine type on antibody levels**: - Individuals vaccinated with the Moderna vaccine had the highest median anti - S antibody levels, followed by Pfizer and Johnson & Johnson vaccines. - Vaccinees of Johnson & Johnson vaccine had lower sensitivities, ranging from 70.4% (Siemens) to 96.3% (Beckman). - Booster shots and natural infections significantly increased the overall antibody levels. - **Demographic factors and side effects**: - Younger individuals and those closer to the last vaccination time showed higher anti - S antibody levels. - Individuals with higher anti - S antibody levels experienced more side effects, such as muscle pain, chills, fever, and moderate limitations. - Anti - N antibody levels were only significantly associated with headache. ### Conclusion: This study provides a comparison of the performance of different anti - S and anti - N assays in different vaccinated populations, emphasizing the importance of using the same platform and assays in large - scale studies. The research results are helpful for better understanding the immune response to SARS - CoV - 2 vaccines and their influencing factors.